202 related articles for article (PubMed ID: 31605028)
1. Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
An JN; Hyeon JS; Jung Y; Choi YW; Kim JH; Yang SH; Oh S; Kwon S; Lee SH; Cho JH; Park SH; Ha H; Kim DK; Lee JP; Hwang GS
Sci Rep; 2019 Oct; 9(1):14707. PubMed ID: 31605028
[TBL] [Abstract][Full Text] [Related]
2. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V; López D; Boixadera E; Ibernón M; Espinal A; Bonet J; Romero R
BMC Nephrol; 2017 Feb; 18(1):49. PubMed ID: 28158993
[TBL] [Abstract][Full Text] [Related]
3. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
[TBL] [Abstract][Full Text] [Related]
4. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.
Ramezani A; Devaney JM; Cohen S; Wing MR; Scott R; Knoblach S; Singhal R; Howard L; Kopp JB; Raj DS
Eur J Clin Invest; 2015 Apr; 45(4):394-404. PubMed ID: 25682967
[TBL] [Abstract][Full Text] [Related]
5. [The clinic significance of urinary podocytes in patients with focal segmental glomerulosclerosis].
Li YH; Huang HC; Liu G; Zhang YK
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):135-8. PubMed ID: 15100729
[TBL] [Abstract][Full Text] [Related]
6. Urinary fibrinogen and renal tubulointerstitial fibrinogen deposition: Discriminating between primary FSGS and minimal change disease.
Wang Y; Zheng C; Xu F; Liu Z
Biochem Biophys Res Commun; 2016 Sep; 478(3):1147-52. PubMed ID: 27539323
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the Japanese Biomarkers in Nephrotic Syndrome (J-MARINE) study.
Kurasawa S; Kato S; Ozeki T; Akiyama S; Ishimoto T; Mizuno M; Tsuboi N; Kato N; Kosugi T; Maruyama S;
Clin Exp Nephrol; 2024 May; 28(5):431-439. PubMed ID: 38267800
[TBL] [Abstract][Full Text] [Related]
8. Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.
Pereira LHM; da Silva CA; Monteiro MLGDR; Araújo LS; Rocha LP; Reis MBDR; Ramalho FS; Corrêa RRM; Silva MV; Reis MA; Machado JR
PLoS One; 2019; 14(6):e0217569. PubMed ID: 31188898
[TBL] [Abstract][Full Text] [Related]
9. Indications for kidney biopsy in idiopathic childhood nephrotic syndrome.
Alshami A; Roshan A; Catapang M; Jöbsis JJ; Kwok T; Polderman N; Sibley J; Sibley M; Mammen C; Matsell DG;
Pediatr Nephrol; 2017 Oct; 32(10):1897-1905. PubMed ID: 28540445
[TBL] [Abstract][Full Text] [Related]
10. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
[TBL] [Abstract][Full Text] [Related]
11. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.
Garin EH; Mu W; Arthur JM; Rivard CJ; Araya CE; Shimada M; Johnson RJ
Kidney Int; 2010 Aug; 78(3):296-302. PubMed ID: 20485332
[TBL] [Abstract][Full Text] [Related]
12. Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.
Huang Z; Zhang Y; Zhou J; Zhang Y
Biomed Res Int; 2017; 2017():7298160. PubMed ID: 28246603
[No Abstract] [Full Text] [Related]
13. Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients.
Navarro-Muñoz M; Ibernon M; Pérez V; Ara J; Espinal A; López D; Bonet J; Romero R
Nephrol Dial Transplant; 2011 Dec; 26(12):3914-23. PubMed ID: 21414970
[TBL] [Abstract][Full Text] [Related]
14. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
[TBL] [Abstract][Full Text] [Related]
15. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
16. Synaptopodin immunoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulosclerosis.
Wagrowska-Danilewicz M; Danilewicz M
Nefrologia; 2007; 27(6):710-5. PubMed ID: 18336100
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.
Mishra OP; Kumar R; Narayan G; Srivastava P; Abhinay A; Prasad R; Singh A; Batra VV
Pediatr Nephrol; 2017 Aug; 32(8):1355-1361. PubMed ID: 28210837
[TBL] [Abstract][Full Text] [Related]
18. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
[TBL] [Abstract][Full Text] [Related]
19. Serum-soluble urokinase receptor concentration in primary FSGS.
Maas RJH; Wetzels JFM; Deegens JKJ
Kidney Int; 2012 May; 81(10):1043-1044. PubMed ID: 22543906
[No Abstract] [Full Text] [Related]
20. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
BMC Med; 2014 May; 12():81. PubMed ID: 24884842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
